Direct compression of methylphenidate hydrotalcite into an immediate-release tablet requires an assay-corrected active complex loading because the hydrotalcite carrier contributes mass that is not counted as methylphenidate base. If the certificate of analysis records 30% w/w methylphenidate base on the hydrotalcite matrix, a 10 mg dose requires 33.3 mg of the complex. A starting core formula of 150.0 mg contains 33.3 mg active complex, 66.0 mg microcrystalline cellulose PH102, 39.0 mg lactose monohydrate, 7.5 mg crospovidone, 3.0 mg sodium starch glycolate, 0.70 mg colloidal silicon dioxide, and 0.50 mg magnesium stearate. Blend uniformity is assessed by sampling at least 10 locations and testing per USP <905>. Powder flow is characterized by USP <616>; compacts are evaluated on a rotary tablet press with B-tooling and a compression force range of 8 kN to 18 kN. Precompression at 2-4 kN reduces lamination caused by hydrotalcite plate-like particles. Tablet hardness is adjusted to 60-90 N to balance disintegration below 15 min in water at 37°C per USP <701> and dissolution per USP <711>. The batch-to-batch variance in hydrotalcite platelet size influences feed shoe turbulence and weight variability on high-speed presses; the suction fill cam should be set to avoid die table spillage.

The hygroscopic nature of the hydrotalcite interlayer requires storage of the blend at 25±2°C and 35±5% RH; blending time should not exceed 20 min because over-mixing deaggregates carrier particles and increases fines below 75 µm. Direct compression should be avoided when ambient relative humidity exceeds 60% unless the blend is kept in closed transfer vessels. Assay of the hydrotalcite complex is performed by validated HPLC under USP <621>; the absence of a harmonized monograph for methylphenidate hydrotalcite places the analytical burden on the manufacturer. Magnesium and aluminum from the carrier are controlled under ICH Q3D (R2) for the oral route. Residual solvents from any pre-intercalation synthesis step are limited by ICH Q3C. The direct-compression process is suitable only for an immediate-release tablet with release not slower than the methylphenidate hydrochloride comparator in 0.1 N HCl at 37°C; if the hydrotalcite matrix delays release beyond 30 min, wet granulation or multiparticulate design is required.

Does High-Shear Wet Granulation Alter the Release-Rate Function of Hydrotalcite-Bound Methylphenidate?

Unlike direct compression, high-shear wet granulation introduces water into the hydrotalcite gallery and changes the thermal history of the carrier before tableting. The granulation endpoint is not defined by a single torque value because the hydrotalcite interlayer water behaves as a plasticizing liquid at high shear. When the wet mass passes through a 10 L high-shear granulator with top-drive impeller at 150-250 rpm and chopper at 1000-1500 rpm, water addition between 18% w/w and 22% w/w of dry mass forms granules with a bimodal size distribution. Drying in a fluid bed at 50°C product temperature must not exceed 60°C because thermal dehydration of the hydrotalcite gallery can shift the carrier’s basal spacing and change the apparent dissolution lag time in phosphate buffer at pH 6.8. X-ray powder diffraction per USP <941> may be used to confirm retention of the layered double hydroxide structure after drying. After drying to LOD 1.5-2.0% w/w by USP <731>, the granules are screened through 1000 µm and 150 µm sieves; the 150-1000 µm fraction is tableted with extragranular crospovidone at 3% w/w.

The granulation fluid may contain povidone K30 at 5% w/w of dry powder; higher binder levels above 7% w/w create hard granules that resist disintegration and prolong release beyond the immediate-release specification. Granule flow is tested by Ph. Eur. 2.9.36; the angle of repose for acceptable flow is below 35°. Release-rate comparisons between direct compression and wet granulation batches should be performed under USP <711> Apparatus II with 50 rpm paddle speed and 900 mL of 0.1 N HCl. If the hydrotalcite interlayer undergoes anion exchange with chloride, the matrix loses its acid-neutralizing function and may release methylphenidate faster. Published data for this specific configuration is limited; pilot-scale granulation trials should include a matrix-matched placebo to isolate the contribution of the hydrotalcite carrier to torque and drying rate.

Extended-Release Multiparticulate Coating Curing and Capsule Filling Parameters

Fluidized-bed rotor processing for extended-release multiparticulates begins with suspension layering of methylphenidate hydrotalcite onto microcrystalline cellulose spheres of 500-600 µm. The suspension solids content for spray layering is typically 10-15% w/w, with hydroxypropyl methylcellulose E5 as binder at 5% w/w of solids. Inlet air temperature is maintained at 40-50°C to avoid premature dehydration of the hydrotalcite carrier; spray rate is adjusted to keep product temperature below 30°C during the active layering phase. After drug layering, the multiparticulates are coated with an aqueous dispersion of ethylcellulose with hypromellose as pore former at 10-15% w/w of polymer weight; the weight gain for an 8-12 h release profile is determined by dissolution data rather than fixed film thickness.

Curing at 60°C for 2 h coalesces the film without causing hydrotalcite interlayer water loss. The finished spheres are sieved through 840 µm and 500 µm screens; the accepted fraction is filled into hard gelatin or hypromellose capsules on an automatic capsule filler with dosing disc size selected by tapped density. Content uniformity follows USP <905>. Dissolution is evaluated in USP <711> Apparatus I at 100 rpm with acid stage for 2 h followed by phosphate buffer at pH 6.8 for 10 h. The acid-neutralizing capacity of the hydrotalcite carrier may buffer local pH in the acid stage; this effect is batch-dependent and must be monitored because it can slow the initial release of methylphenidate from sustained-release multiparticulates.

Thermal dehydration thresholds govern the sachet stability of dispersible methylphenidate hydrotalcite granules

If sachet stability is to be maintained in flavored oral suspension vehicles, the hydrotalcite framework’s staged water release must be anticipated during granulation and packaging. Granules for oral suspension are produced by wet granulation and dried to LOD 1.0-1.5% w/w; residual moisture above 2.0% w/w accelerates settling and caking in sachets stored at 25°C/60% RH. A typical formulation contains 10% w/w active complex, 58% w/w sucrose or mannitol, 20% w/w microcrystalline cellulose, 5% w/w sodium starch glycolate, 3% w/w citric acid, 1.5% w/w xanthan gum, and 2.5% w/w flavor and sweetener blend. Sieve analysis by Ph. Eur. 2.9.12 should retain not more than 15% w/w below 180 µm to limit foam formation upon reconstitution; particles above 710 µm cause rapid sedimentation and poor dose pour-ability.

Moisture vapor transmission rate of the primary sachet material is specified below 0.5 g/(m²·24 h) at 38°C/90% RH according to ASTM F1249-20. Suspension pH after reconstitution using 20 mL of water should be 4.0-5.0; below 3.5, the hydrotalcite lattice dissolves and releases aluminum and magnesium ions, which may exceed the corresponding ICH Q3D (R2) oral permitted daily exposure values if the dose is not adjusted. The reconstituted suspension may be used under refrigeration at 2-8°C; development targets of 7-14 days are common, but no fixed in-use shelf life can be assigned without matrix-specific microbial and physical stability data. Freeze-thaw cycling is not recommended because interlayer collapse may alter the sedimentation volume ratio.

Orally disintegrating tablet manufacture exposes the hydrotalcite carrier to a friability-hardness conflict when the tablet must disintegrate in 30 s or less using the manufacturer’s in-house simulated salivary fluid method at 37°C. The plate-like hydrotalcite particles increase the internal friction of the dry blend and lower radial tensile strength when direct compression is used. Freeze-dried ODT formulations avoid this by using a suspension of active complex in a matrix of gelatin or pullulan, mannitol, and glycine; the drug is suspended rather than dissolved because the hydrotalcite carrier is insoluble in the aqueous feed solution. The suspension is dosed into preformed pockets at 500 mg wet weight and lyophilized over 36-48 h with primary drying at -20°C and secondary drying at 25°C. Residual moisture is kept below 1.5% w/w; the resulting tablets disintegrate in 10-30 s in simulated salivary fluid at pH 6.8.

A direct-compression ODT alternative uses mannitol-based co-processed excipients at 75-80% w/w, crospovidone at 5-8% w/w, and active complex at 10-15% w/w; hardness is capped at 40 N to preserve disintegration. Taste-masking effectiveness of the hydrotalcite complex has not been confirmed in published comparative studies; a sweetener and flavor system of sodium saccharin 0.5% w/w plus peppermint oil 0.3% w/w may be used only after sensory evaluation. Direct-compression ODT batches should be equilibrated at 20-25°C and 30-40% RH before compression; exposure above 60% RH causes surface tackiness and increases punch sticking on multi-tip tooling.

When Methylphenidate Hydrotalcite Is Pre-Dissolved for Sterile Injectable Solutions, Particulate Matter Limits Tighten

For sterile injectable solutions, the layered double hydroxide carrier must first be dissolved in an acidic aqueous medium because the intact hydrotalcite matrix is not soluble and cannot be administered intravenously. The API complex is suspended in cold Water for Injection, acidified with dilute hydrochloric acid to pH 2.0-2.5 under stirring for 15-30 min, and then neutralized to pH 5.5-6.5 with sodium hydroxide. The resulting solution contains methylphenidate hydrochloride and dissolved magnesium and aluminum chlorides; these ions are not acceptable as particulate matter but are controlled by ICH Q3D (R2) elemental impurity limits for the parenteral route. The solution is passed through a 0.22 µm PVDF or PES membrane filter; filter compatibility must be tested because dissolved hydrotalcite-derived cations can form insoluble complexes with phosphate buffers.

A 5 mg/mL methylphenidate injection is adjusted to 290-310 mOsmol/kg with sodium chloride and filled into Type I borosilicate glass vials under nitrogen overlay. Terminal sterilization at 121°C for 15 min is preferred; aseptic filtration is used when terminal sterilization data show unacceptable assay loss. In-process bioburden before filtration is controlled below 10 CFU/100 mL; endotoxin is tested by USP <85> with a limit appropriate to the maximum daily dose. Subvisible particulate matter is measured by light obscuration per USP <788>; visible particulates are inspected per USP <790>.

The hydrotalcite carrier can be used only as an intermediate in injectable manufacture; if the final product is a suspension intended for intramuscular administration, particle size must be reduced by wet milling to d90 below 10 µm and verified by laser diffraction with ISO 13320:2020. Because methylphenidate is a Schedule II controlled substance under 21 CFR 1308.12(d), cage-level accountability and waste quantification are required; this does not change the technical unit operations but affects batch documentation. Injection, whether solution or suspension, demands dedicated cleaning validation because the inorganic carrier leaves an inorganic residue on filling needles and sterilizing filters if the pre-release step is incomplete.